Skip to main content
Journal cover image

A phase II trial of concurrent chemoradiotherapy with weekly docetaxel plus cisplatin treatment for unresectable locally advanced head and neck cancer

Publication ,  Journal Article
Lee, JY; Sun, JM; Oh, D; Lim, SH; Chi, S; Lee, SH; Jung, SH; Ahn, MJ; Ahn, YC; Park, K
Published in: Radiotherapy and Oncology
February 1, 2017

Purpose Although concurrent chemoradiotherapy (CCRT) is the standard of care for locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN), the optimal CCRT regimen is not yet defined. We conducted a phase II study of weekly docetaxel and cisplatin treatment with concurrent radiotherapy (RT) to investigate the efficacy and toxicity profiles. Material and methods Forty-one patients with locally advanced SCCHN were treated with 20 mg/m2 docetaxel plus 20 mg/m2 cisplatin weekly for 6 cycles, concurrent with RT, between April 2010 and March 2013. Results The mean total doses of docetaxel and cisplatin were 109.3 mg/m2 and 110.7 mg/m2, respectively. The mean total delivered dose of radiation was 67.7 Gy. Thirty-seven patients (90.3%) received 5 or more cycles of treatment. At the 1-month post-CCRT tumor response evaluation, 13 patients (39.9%) achieved a complete response (CR) [95% confidence interval (95% CI), 20.1–56.6]. Thirty-two patients (78.0%) ultimately achieved CR during the post-treatment follow-up period. With a median follow-up of 3.4 years, the 2-year overall survival (OS), disease-free survival (DFS), and distant disease-free survival (DDFS) were 85.4% (95% CI, 74.6–96.2%), 72.8% (95% CI, 59.2–86.4%), and 82.4% (95% CI, 70.7–94.1%), respectively. Overall, grade 3 toxicities occurred in 21 patients (51.2%), most commonly mucositis (39.0%), neutropenia (9.8%), or dysphagia (4.9%). A grade 4 adverse event was observed in only one patient with neutropenia. Conclusions CCRT with weekly docetaxel and cisplatin shows promising antitumor activity with manageable toxicity profiles for patients with locally advanced SCCHN.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Radiotherapy and Oncology

DOI

EISSN

1879-0887

ISSN

0167-8140

Publication Date

February 1, 2017

Volume

122

Issue

2

Start / End Page

217 / 223

Related Subject Headings

  • Oncology & Carcinogenesis
  • 5105 Medical and biological physics
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
  • 0299 Other Physical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lee, J. Y., Sun, J. M., Oh, D., Lim, S. H., Chi, S., Lee, S. H., … Park, K. (2017). A phase II trial of concurrent chemoradiotherapy with weekly docetaxel plus cisplatin treatment for unresectable locally advanced head and neck cancer. Radiotherapy and Oncology, 122(2), 217–223. https://doi.org/10.1016/j.radonc.2016.09.015
Lee, J. Y., J. M. Sun, D. Oh, S. H. Lim, S. Chi, S. H. Lee, S. H. Jung, M. J. Ahn, Y. C. Ahn, and K. Park. “A phase II trial of concurrent chemoradiotherapy with weekly docetaxel plus cisplatin treatment for unresectable locally advanced head and neck cancer.” Radiotherapy and Oncology 122, no. 2 (February 1, 2017): 217–23. https://doi.org/10.1016/j.radonc.2016.09.015.
Lee JY, Sun JM, Oh D, Lim SH, Chi S, Lee SH, et al. A phase II trial of concurrent chemoradiotherapy with weekly docetaxel plus cisplatin treatment for unresectable locally advanced head and neck cancer. Radiotherapy and Oncology. 2017 Feb 1;122(2):217–23.
Lee, J. Y., et al. “A phase II trial of concurrent chemoradiotherapy with weekly docetaxel plus cisplatin treatment for unresectable locally advanced head and neck cancer.” Radiotherapy and Oncology, vol. 122, no. 2, Feb. 2017, pp. 217–23. Scopus, doi:10.1016/j.radonc.2016.09.015.
Lee JY, Sun JM, Oh D, Lim SH, Chi S, Lee SH, Jung SH, Ahn MJ, Ahn YC, Park K. A phase II trial of concurrent chemoradiotherapy with weekly docetaxel plus cisplatin treatment for unresectable locally advanced head and neck cancer. Radiotherapy and Oncology. 2017 Feb 1;122(2):217–223.
Journal cover image

Published In

Radiotherapy and Oncology

DOI

EISSN

1879-0887

ISSN

0167-8140

Publication Date

February 1, 2017

Volume

122

Issue

2

Start / End Page

217 / 223

Related Subject Headings

  • Oncology & Carcinogenesis
  • 5105 Medical and biological physics
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
  • 0299 Other Physical Sciences